The rumors of Pfizer Inc.’s interest in a mega-purchase of Seagen Inc. became true on 13 March when the companies announced that the big pharma would pay $43bn in cash for the antibody-drug conjugate (ADC) pioneer. Confirming the deal gave Pfizer an opportunity to outline its big oncology ambitions not only for the Seagen assets but for the combined company going forward.
Pfizer said Seagen’s four approved products – three ADCs and a small molecule cancer drug – plus candidates in its pipeline should generate $10bn in annual revenue by 2030
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?